Zacks Research Brokers Reduce Earnings Estimates for TSE:BHC

Key Points

• Zacks Research lowered its FY2025 earnings per share estimate for Bausch Health Companies Inc. to $5.23, down from the previous estimate of $5.27.
• The company's stock opened at C$10.43, with a market capitalization of C$2.71 billion and a price-to-earnings ratio of -15.26.
• Insiders, including Director John Paulson, purchased over 3.5 million shares of the company's stock recently, indicating confidence in the firm's future.

Bausch Health Companies Inc. (TSE:BHC - Free Report) - Stock analysts at Zacks Research cut their FY2025 earnings per share (EPS) estimates for shares of Bausch Health Companies in a research report issued to clients and investors on Wednesday, August 20th. Zacks Research analyst Team now forecasts that the company will earn $5.23 per share for the year, down from their previous forecast of $5.27. The consensus estimate for Bausch Health Companies' current full-year earnings is $5.55 per share. Zacks Research also issued estimates for Bausch Health Companies' Q4 2025 earnings at $1.66 EPS, Q3 2026 earnings at $1.61 EPS, FY2026 earnings at $5.64 EPS, Q1 2027 earnings at $1.43 EPS, Q2 2027 earnings at $1.43 EPS and FY2027 earnings at $6.39 EPS.

Bausch Health Companies Stock Up 0.2%

BHC traded up C$0.02 during trading on Friday, hitting C$9.96. 101,426 shares of the company's stock traded hands, compared to its average volume of 382,382. The stock has a market capitalization of C$2.59 billion, a price-to-earnings ratio of -14.58, a PEG ratio of 0.21 and a beta of 0.77. Bausch Health Companies has a 12-month low of C$5.91 and a 12-month high of C$13.74. The company has a current ratio of 1.19, a quick ratio of 0.58 and a debt-to-equity ratio of -1,831.94. The company's 50 day simple moving average is C$9.14 and its two-hundred day simple moving average is C$8.42.

Insider Activity

In related news, Director John Paulson purchased 1,782,030 shares of the firm's stock in a transaction dated Friday, June 13th. The stock was purchased at an average price of C$8.14 per share, with a total value of C$14,501,803.73. Insiders purchased a total of 3,553,401 shares of company stock worth $27,087,675 in the last ninety days. 11.28% of the stock is owned by insiders.

About Bausch Health Companies

Bausch Health Companies Inc operates as a diversified specialty pharmaceutical and medical device company in the United States and internationally. It develops, manufactures, and markets a range of products primarily in gastroenterology, hepatology, neurology, dermatology, international pharmaceuticals, over-the-counter (OTC) products, aesthetic medical devices, and eye health.